Market Cap | 10.50M | P/E | - | EPS this Y | 17.50% | Ern Qtrly Grth | - |
Income | -11.12M | Forward P/E | -0.35 | EPS next Y | 14.30% | 50D Avg Chg | -21.00% |
Sales | - | PEG | -0.01 | EPS past 5Y | - | 200D Avg Chg | -57.00% |
Dividend | N/A | Price/Book | 1.04 | EPS next 5Y | 15.00% | 52W High Chg | -87.00% |
Recommedations | 2.50 | Quick Ratio | 6.44 | Shares Outstanding | 2.86M | 52W Low Chg | 19.00% |
Insider Own | 11.27% | ROA | -99.41% | Shares Float | 2.49M | Beta | 0.52 |
Inst Own | 1.96% | ROE | -178.52% | Shares Shorted/Prior | 35.81K/67.30K | Price | 0.43 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 118,840 | Target Price | 80.00 |
Oper. Margin | - | Earnings Date | May 13 | Volume | 160,312 | Change | 1.54% |
Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.
Benchmark | Speculative Buy | Mar 6, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Lin Patrick | Chief Business - Str.. Chief Business - Strategy Off | Jan 31 | Buy | 2.39 | 4,000 | 9,560 | 27,478 | 02/01/24 |
Ng George K | Chief Executive Offi.. Chief Executive Officer | Jan 30 | Buy | 2.7 | 10,000 | 27,000 | 20,000 | 01/31/24 |
Young David | President & CEO President & CEO | Apr 14 | Buy | 0.5499 | 20,000 | 10,998 | 430,424 | 04/14/23 |
Young David | President & CEO President & CEO | Apr 11 | Buy | 0.48 | 60,000 | 28,800 | 410,424 | 04/13/23 |
Lin Patrick | Chief Business - Str.. Chief Business - Strategy Off | May 17 | Buy | 1.5945 | 2,000 | 3,189 | 433,390 | 05/19/22 |
Lin Patrick | Chief Business - Str.. Chief Business - Strategy Off | Apr 06 | Buy | 3.34 | 2,000 | 6,680 | 431,390 | 04/08/22 |
Yorke Justin W | Director Director | Jan 27 | Sell | 3.30 | 1,854 | 6,118 | 532,563 | 01/31/22 |